AdaptHealth (AHCO) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.07
- Estimate
- $0.17
- Surprise
- -139.5%
- Revenue (period 2026-06-30)
- $740.3M
- Score today
- 5.4/10
Revenue source: xbrl.
How the report landed
AdaptHealth (AHCO) reported a wider loss than forecast — adjusted EPS of -$0.07 against the $0.17 estimate (a 139.5% shortfall).
Where TrendMatrix's rating stands now
TrendMatrix currently rates AHCO Sell at 5.4/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate; this quarter's -139.5% surprise compares with a -119.2% four-quarter average. Next scheduled report: 2026-11-03.
What argues against it
- Quality below floor (1.6 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $6.28
- Price target
- $7.71
- Stop
- $5.84
- Upside to target
- +22.8%
- Reward-to-risk
- 2.3:1
Risk check: trading volume is running 3.2× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-11-04 — shown for context, not personalized investment advice.
AHCO at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Devices
- Market cap
- $854.4M
- P/E (fwd)
- -34.9
- 52-week range
- $5.21–$13.43
- Off 52-week high
- 53.2%
- RSI (14)
- 51
- Volume vs avg
- 3.17×
- Score today
- 5.4/10